Quidel Stock Price, News & Analysis

QuidelOrtho (NASDAQ: QDEL) released the 50th episode of its Science Bytes podcast featuring Dr. Jonathan Temte from the University of Wisconsin-Madison discussing respiratory virus prevention in schools. The episode focuses on seasonal health challenges including influenza, RSV, COVID-19, and vaccine-preventable diseases.

Dr. Temte emphasizes three key strategies: early detection through rapid diagnostics for targeted treatment, monitoring absenteeism data to predict outbreaks, and implementing preventive measures to reduce disease transmission in schools and homes. The podcast is available on major streaming platforms and QuidelOrtho's website.

QuidelOrtho (NASDAQ: QDEL) has appointed Erich Wolff as Executive Vice President of Strategy & Corporate Development, reporting to CEO Brian Blaser. Wolff brings over 20 years of leadership experience in healthcare, diagnostics, and MedTech sectors.

Previously serving as Buyouts Lead at Partners Group ($174B AUM), Wolff held senior roles at BD and Medtronic. At Medtronic, he revitalized the global diabetes business and managed corporate development for $11.5B neurosciences and diabetes units. At BD, he led key transactions including the embecta spinoff and $1.5B Parata Systems acquisition.

QuidelOrtho (NYSE:QDEL) has launched its Certified Analyzer Program, aimed at expanding access to diagnostic testing in rural and community hospitals across the United States. The initiative focuses on healthcare facilities with fewer than 100 beds, offering certified VITROS™ analyzers at reduced costs.

The program features certified VITROS XT 7600, 5600 Integrated Systems, and VITROS 3600 Immunodiagnostic System. Each analyzer undergoes a rigorous certification process including over 140 system checks, hardware maintenance, and performance testing at QuidelOrtho's Rochester facility. The certified analyzers come with a 12-month warranty on service and support.

QuidelOrtho (NASDAQ: QDEL) reported Q2 2025 financial results with total revenue of $614 million. The company's Labs revenue grew 4% as reported and 5% in constant currency, while Immunohematology revenue increased by 4% as reported. However, respiratory revenue declined 20% to $47 million due to lower COVID-19 revenue.

The company reported a GAAP net loss margin of (42%) and GAAP diluted loss per share of $3.77. Adjusted EBITDA margin improved by 330 basis points to 17%, with adjusted diluted EPS of $0.12. QuidelOrtho achieved its targeted $100 million annualized cost savings and reiterated its full-year 2025 guidance with expected revenues of $2.60-$2.81 billion.

QuidelOrtho (NYSE:QDEL) has secured three prestigious awards in the 2025 IMV ServiceTrak™ Awards, demonstrating excellence in customer satisfaction. The company received awards for Best Overall System Performance in both Chemistry and Integrated Systems categories, along with Best Overall Service for Integrated Systems.

The company achieved #1 rankings in multiple categories including Overall Net Promoter Score, Manufacturer Performance, Service Engineer Performance, and Training Performance. Notably, QuidelOrtho recorded a 17-point increase in NPS, marking the largest gain in the category.

QuidelOrtho (NYSE:QDEL) released Episode 49 of its Science Bytes podcast, focusing on the critical role of rapid diagnostic testing in drug overdose cases. The episode features Vonda McAllister, Director of Global Product Management, discussing urgent challenges in emergency departments amid rising drug complexities.

The podcast highlights several key issues including the limitations of Narcan, the increasing prevalence of synthetic drugs like fentanyl and xylazine, and the implementation of California's Tyler's Law mandating fentanyl testing. The discussion emphasizes how rapid diagnostic testing can improve clinical decision-making and potentially save lives in emergency care settings.

QuidelOrtho (NASDAQ: QDEL), a global provider of in vitro diagnostic technologies, has scheduled its second quarter 2025 financial results announcement for Tuesday, August 5, 2025, after market close.

The company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss the results. Investors can access the webcast through QuidelOrtho's investor relations website, or join via phone using specific dial-in numbers. Presentation materials will be available on the company's website concurrent with the call.

QuidelOrtho (NASDAQ: QDEL) has announced a featured session at the upcoming Association for Diagnostics & Laboratory Medicine (ADLM) meeting, focusing on Six Sigma metrics in laboratory performance. The session, titled "Real Labs, Real Decisions with Actionable Six Sigma Metrics," will take place on July 29, 2025 at the McCormick Convention Center in Chicago.

The panel discussion will feature experts including Dr. Jared Jaeger as moderator, along with distinguished professionals from the University of Florida PathLab, St. Peter's University Hospital, and UHS Hospitals. The session will explore how QuidelOrtho's Six Sigma tools and real-world laboratory data can be utilized to enhance quality outcomes in clinical settings.

QuidelOrtho (NASDAQ: QDEL) and BÜHLMANN Laboratories AG have announced the integration of two key diagnostic assays on VITROS Systems: the fCAL turbo for inflammatory bowel disease (IBD) detection and fPELA turbo for pancreatic insufficiency diagnosis.

The assays feature rapid results delivery in under 10 minutes, wide reportable ranges, and 90-day analyzer stability. Both tests utilize BÜHLMANN's innovative CALEX Cap technology for simplified sample extraction and are available on VITROS XT 7600, 5600 Integrated System, and 4600 Chemistry Systems.

This partnership aims to enhance non-invasive diagnostic capabilities while reducing healthcare costs and the need for invasive procedures in gastrointestinal and pancreatic health diagnostics.